Bio-Rad Laboratories has climbed back into focus after a mixed share price record, and the key issue now is whether the ...

Bio-Rad Laboratories (BIO) drew fresh attention after CFO Roop K. Lakkaraju was slated for a fireside chat at the UBS Global ...

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

*The ddPCR assays manufactured by Bio-Rad Laboratories are for Research Use Only (RUO) and are not intended for use in diagnostic procedures. Any clinical use or clinical claims made by customers or ...

The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth ...

Fintel reports that on April 7, 2026, Citigroup downgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral. Analyst Price Forecast Suggests 22.54% Upside As of March 27, 2026, ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Bio-Rad Laboratories BIO is balancing improving digital PCR demand and a recurring diagnostics base against a valuation that ...

Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...